GlassScriptPhysician profile
Eugene C Lai
NPI 1790871002
$19,783.48
in general payments reported to CMS, 2019-2025
57 companies · $1,763 in 2025
The $1,763 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,862 · 2020: $3,468 · 2021: $2,111 · 2022: $1,873 · 2023: $3,240 · 2024: $2,466 · 2025: $1,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,309 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,309.02 |
| Education | $161.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,907.80 | 2019-2025 | |
| Acorda Therapeutics, INC | $2,180.77 | 2019-2021 | |
| Emd Serono, INC. | $1,102.68 | 2019-2023 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $1,088.41 | 2019-2025 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $1,041.73 | 2019-2025 | Nuplazid |
| Csl Behring | $876.37 | 2019-2025 | Hizentra |
| Abbvie INC. | $861.56 | 2019-2025 | |
| Ucb, INC. | $795.29 | 2019-2024 | Briviact, Rystiggo |
| Otsuka America Pharmaceutical, INC. | $720.27 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $542.67 | 2020-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $541.53 | 2019-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $515.68 | 2020-2025 | Crexont, Rytary, Ongentys |
| Biogen, INC. | $481.99 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Amgen INC. | $479.46 | 2019-2025 | Uplizna |
| Boston Scientific Corporation | $469.64 | 2019-2025 | General - Dbs |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.